This is a contract award for Norgestimate Ethinyl Estradiol Triphasic Low Dose Oral Tablets. The contract includes a base year and four option years. The estimated total value for the 5-year period is $4,229,263. 40. The manufacturing and performance location is Spain, with Laboratorios Leon Farma SAU as the CMO for Xiromed. The U. S. point of contact is Ashton Mattingly. The contract incorporates by reference various Federal Acquisition Regulation (FAR) clauses. The document also lists current pharmaceutical prime vendors.
The bid notice does not explicitly state a delivery deadline for the products. However, the contract includes a base year and four option years, with the option year 1 effective from April 27, 2026, through April 26, 2027.
The bid notice does not explicitly detail the payment terms. However, it does reference FAR clauses related to payment by electronic funds transfer and installment payments for commercial products and services.
The bid notice indicates that Avkare, LLC's offer dated 1/23/2025, with a final proposal revision on 3/1/2025, is being accepted by the government to form this contract. The specific award criterion used is not explicitly stated in the provided text.
The bid notice does not explicitly state qualification criteria for bidders. However, it does reference various FAR clauses related to contractor responsibility and small business concerns.
The bid notice does not explicitly mention penalties for non-compliance. However, it does reference FAR clauses related to liquidated damages for subcontracting plans.
The bid notice does not explicitly state a deadline for challenges or protests. However, it does reference FAR clause ****, Protest After Award.
The bid notice states that his contract is estimated at $4,229,**** for 5 years.